Related Experiment Video

Updated: Dec 6, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.5K

MUC1 antibody-based therapeutics: the promise of cancer immunotherapy

Mona Pourjafar1,2, Pouria Samadi1,2, Massoud Saidijam2

  • 1Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Immunotherapy
|October 6, 2020
PubMed

Insights

Targeted cancer therapies utilize antibody treatments to specifically attack tumors. This review focuses on MUC1 (mucin 1), a key tumor marker, and evaluates antibody-based strategies for improved cancer immunotherapy.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Antibody-based therapies offer high specificity and efficacy in cancer treatment.
  • Identifying tumor-specific or tumor-associated antigens is critical for targeted cancer therapies.
  • MUC1 is a significant tumor marker overexpressed in various solid tumors, making it a promising therapeutic target.

Purpose of the Study:

  • To review preclinical and clinical findings of MUC1-targeting antibody-based therapies.
  • To explore different antibody platforms including monoclonal antibodies, nanobodies, and bispecific antibodies against MUC1.
  • To identify current challenges and future directions for MUC1-targeted cancer immunotherapy.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of data from various antibody-based platforms targeting MUC1.
  • Synthesis of information on therapeutic and diagnostic applications of MUC1-targeting agents.

Main Results:

  • MUC1 is a validated target for antibody-based cancer therapies.
  • Various antibody formats (monoclonal, nanobodies, bispecific) have shown promise against MUC1.
  • Preclinical and clinical data demonstrate the potential of MUC1-targeted approaches.

Conclusions:

  • MUC1-targeting antibody therapies represent a viable strategy for cancer treatment.
  • Further research is needed to overcome existing challenges and enhance treatment efficacy.
  • Optimizing antibody platforms and understanding resistance mechanisms are key for future immunotherapy development.
Keywords:
MUC1antibodybispecific antibodycancerimmunotherapymonoclonal antibodiesmucintargeted therapy

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.4K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

904

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
852